Principia Biopharma Inc (Principia Biopharma) is a clinical stage biopharmaceutical company. It designs and develops oral small molecule drug therapies for immune disorders and cancer. The company, through its proprietary Tailored Covalency platform, develops a portfolio of drug candidates such as rilzabrutinib, PRN473 Topical, PRN2246 and immunoproteasome inhibitor. Its rilzabrutinib drug candidated, is used for the treatment of pemphigus vulgaris, immune thrombocytopenia and IgG4-related diseases, is a reversible covalent BTK inhibitor. PRN2246, which crosses the blood-brain barrier, is under Phase 1 clinical trial as an oral therapy to treat autoimmunity and neuro-inflammatory diseases. The PRN2246 candidate, under Phase 1 trial, is used in treating MS and central nervous system diseases and immunoproteasome inhibitor for treatment of inflammation and autoimmune disorders. Principia Biopharma is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
220 East Grand Avenue, South San Francisco, California, 94080
Website
www.principiabio.com
Telephone
1 650 4167700
Industry
Pharmaceuticals and Healthcare
Revenue (2019)
$5.2M
Principia Biopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline Product: |
| Rilzabrutinib- BTK Inhibitor for Autoimmune and Inflammatory Diseases |
| PRN2246 - BTK Inhibitor for Multiple Sclerosis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Principia Biopharma Inc | AbbVie Inc | AstraZeneca Plc | Biogen Inc | Protagonist Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
| City | South San Francisco | North Chicago | Cambridge | Cambridge | Newark |
| State/Province | California | Illinois | England | Massachusetts | California |
| No. of Employees | - | 50,000 | 89,900 | 7,570 | 112 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alan B. Colowick, MD | Chairman | Executive Board | - | - |
| Martin Babler | Director; President; Chief Executive Officer | Executive Board | - | - |
| Christopher Y. Chai | Chief Financial Officer | Senior Management | - | - |
| Dolca Thomas | Chief Medical Officer | Senior Management | - | - |
| David Goldstein, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward